actinium-225 – Talk Bio

Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage

9 months ago talkbio0Tagged actinium-225, Isotopes, Myers, Phase 3 trial, Radiopharmaceuticals, RYZ101, shortage, squibb

Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

11 months ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal

11 months ago talkbio0Tagged actinium-225, Isotope Supply, Myers, Neoplasms, Neurosecretory Systems, Radiopharmaceuticals, RayzeBio, squibb

RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors